The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
H very good summary which incorporates known facts, unlike the SP250 'show'. Although, everyone has the right to air their opinions, vexatious and as yet unfounded posts should be treated with the contempt they deserve.
Facts Reminder..I wrote previously and added a couple of new developments..
1.motif main issue is to raise funds which will be known once the fda and motif reach an understanding of the additional trial requirement Which will be known next month.
2.raising funds for a company of future investment blockbuster AB which can generate huge income is a very attractive proposition for many bigger fish to take seriously.
3. Motif is not selling a failing product or raising cash to prompt up a failing company.
4.No warning signs of top management resigning or leaving for a better opportunity.
5.new high profile recruitment Andrew Powell with his reputed success in M&A and surely there must be a purpose of bringing him in and why would he accepts the new position after fda turned down the nda? Surely he would not tarnish his good reputation in the knowledge that motif is going under...seems daft and nonsensical.
6.No signs of auditors,brokers leaving. All staying put with Motif.
7. From the ceo latest interview, webcast...he reassured that a clear path forwards was in place and all bases are covered. Why would he say all this ...obviously not that naive to trying to deceive everyone and destroy the company he was trying to build his reputation on with others in top management. This will be considered market manipulation and abuse that could land him being investigated and in jail for up to 7 years!
8. Again in his last interview he confirmed interesting third parties in usa and outside with ongoing discussions with motif.
9.motif product has been successful in all trials undergone by motif and no death,no efficacy problem or inferiority,no liver damage detection in these trials which were done and as we all understood all were conducted in the prior knowledge of the fda discussion with motif.
10. The need for a new AB like Iclaprim is dire so why raising funds should be a problem at this stage of one more step to success.
11. Why do we think that Iclaprim might fail in another trial while it passed in every past one!?
12.for any third party this is an ideal situation for them to take advantage of motif current weakness and invest for future needed product that can generate huge income.
13.we need to remember that the fda did not reject the nda or Iclaprim but encouraged motif for another trial before approval so I read this as they wanted it to be approved but more data is required to be sure of potential liver toxicity...
14. Big ii are still holding ....
15. Lender Hercules agreed to postpone its debts which a sign of something positive is expected.
16.Yesterday rns was good news for us investors that outside government identity funds ,given to fund Iclaprim in the treatment of Listeria infection. This indicates big interest in Motif Iclaprim AB.
Chin up ,remain positive and ignore the trolls whose interest to see you selling your holdings and collapse of the company to line their pockets as they have taken short positions on Motif.